HealthBeacon PLC HealthBeacon - HBCN - Director/PDMR Shareholding

Healthbeacon

01/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA7958Ea&default-theme=true

RNS Number : 7958E  HealthBeacon PLC  01 November 2022

01 November 2022

HealthBeacon plc

 

Director/PDMR Shareholding

 

Dublin, Ireland - 1 November 2022: HealthBeacon plc (HBCN.ID) ("HealthBeacon"
or "the Company"), a digital therapeutics company that develops products for
managing injectable medications for patients in the home, today announces that
Jim Joyce, Chief Executive Officer and Co-Founder, has purchased 9,439
ordinary shares at a price of €2.10. Following this purchase Jim Joyce holds
1,811,786 shares representing 10.73% of the Company.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of ordinary shares
purchased.

 

 

Notification - of Transactions by Persons Discharging Managerial
Responsibilities and Persons Closely Associated with them

 

 This form is required for disclosure of transactions under Article 19 of
Regulation (EU) No 596/2014 of the European Parliament and of the Council of
16 April 2014 on market abuse (Market Abuse Regulation)

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                             Jim Joyce
 2   Reason for the notification
 a)  Position/status                                                  Person discharging managerial responsibility - Chief Executive Officer
 b)  Initial Notification Amendment                                   Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                             HealthBeacon plc
 b)  LEI                                                              635400DZJITFJMT8T166
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial  instrument, type  of instrument    Ordinary shares of €0.0025 each ("HealthBeacon Shares")

     Identification code

                                                                      IE00014QAJZ5
 b)  Nature of the transaction                                        Purchase of HealthBeacon Shares
 c)  Price(s) and volume(s)

Price(s)                    Volume(s)
                                                                      €2.10 per ordinary share    9,439
 d)  Aggregated information

     - Aggregated volume                                              n/a single transaction

     - Price

 e)  Date of the transaction                                          28 October 2022
 f)  Place of the transaction                                         Euronext Growth Market Dublin
 g)  Additional Information                                           N/A

d)

Aggregated information

- Aggregated volume

- Price

 

n/a single transaction

 

 

 

e)

Date of the transaction

28 October 2022

f)

Place of the transaction

Euronext Growth Market Dublin

g)

Additional Information

N/A

 

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Paul Clifford                                    +353 (0) 87 327 2161

 

About HealthBeacon plc

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Smart
Pills(tm) which integrate with its existing technology. The Company operates
across Europe, North America and the United Kingdom and employs more than 70
people and has obtained more than 30 design and utility patents. The Company's
mission is to become the world's leading digital therapeutics platform for
patients managing medications in the home.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEBKDBQABDDAKN